nodes	percent_of_prediction	percent_of_DWPC	metapath
Terazosin—ABCB1—hematologic cancer	0.188	1	CbGaD
Terazosin—ABCB1—Lenalidomide—hematologic cancer	0.048	0.141	CbGbCtD
Terazosin—ABCB1—Daunorubicin—hematologic cancer	0.0281	0.0826	CbGbCtD
Terazosin—ABCB1—Alitretinoin—hematologic cancer	0.0275	0.0809	CbGbCtD
Terazosin—ABCB1—Imatinib—hematologic cancer	0.0215	0.0633	CbGbCtD
Terazosin—ABCB1—Nilotinib—hematologic cancer	0.0196	0.0575	CbGbCtD
Terazosin—ABCB1—Vinorelbine—hematologic cancer	0.0194	0.057	CbGbCtD
Terazosin—ABCB1—Dasatinib—hematologic cancer	0.0173	0.0508	CbGbCtD
Terazosin—ABCB1—Mitoxantrone—hematologic cancer	0.0171	0.0502	CbGbCtD
Terazosin—ABCB1—Betamethasone—hematologic cancer	0.0152	0.0447	CbGbCtD
Terazosin—ABCB1—Gemcitabine—hematologic cancer	0.0151	0.0443	CbGbCtD
Terazosin—ABCB1—Prednisolone—hematologic cancer	0.015	0.0442	CbGbCtD
Terazosin—ABCB1—Prednisone—hematologic cancer	0.0142	0.0417	CbGbCtD
Terazosin—ABCB1—Irinotecan—hematologic cancer	0.0135	0.0395	CbGbCtD
Terazosin—ABCB1—Vinblastine—hematologic cancer	0.012	0.0351	CbGbCtD
Terazosin—ABCB1—Vincristine—hematologic cancer	0.0118	0.0345	CbGbCtD
Terazosin—ABCB1—Cisplatin—hematologic cancer	0.011	0.0322	CbGbCtD
Terazosin—ABCB1—Etoposide—hematologic cancer	0.0108	0.0317	CbGbCtD
Terazosin—ABCB1—Dexamethasone—hematologic cancer	0.00886	0.026	CbGbCtD
Terazosin—ABCB1—Doxorubicin—hematologic cancer	0.00735	0.0216	CbGbCtD
Terazosin—ABCB1—Methotrexate—hematologic cancer	0.00712	0.0209	CbGbCtD
Terazosin—Prazosin—SLC22A1—hematologic cancer	0.00146	0.434	CrCbGaD
Terazosin—Prazosin—ABCG2—hematologic cancer	0.00102	0.303	CrCbGaD
Terazosin—Doxazosin—ABCB1—hematologic cancer	0.00046	0.137	CrCbGaD
Terazosin—Prazosin—ABCB1—hematologic cancer	0.000424	0.126	CrCbGaD
Terazosin—Rhinitis—Doxorubicin—hematologic cancer	5.63e-05	0.000154	CcSEcCtD
Terazosin—Hypersensitivity—Prednisolone—hematologic cancer	5.59e-05	0.000153	CcSEcCtD
Terazosin—Pharyngitis—Doxorubicin—hematologic cancer	5.57e-05	0.000153	CcSEcCtD
Terazosin—Dyspepsia—Dexamethasone—hematologic cancer	5.57e-05	0.000153	CcSEcCtD
Terazosin—Dyspepsia—Betamethasone—hematologic cancer	5.57e-05	0.000153	CcSEcCtD
Terazosin—Oedema peripheral—Doxorubicin—hematologic cancer	5.53e-05	0.000151	CcSEcCtD
Terazosin—Dysgeusia—Methotrexate—hematologic cancer	5.53e-05	0.000151	CcSEcCtD
Terazosin—Asthenia—Etoposide—hematologic cancer	5.52e-05	0.000151	CcSEcCtD
Terazosin—Body temperature increased—Triamcinolone—hematologic cancer	5.52e-05	0.000151	CcSEcCtD
Terazosin—Anaphylactic shock—Prednisone—hematologic cancer	5.51e-05	0.000151	CcSEcCtD
Terazosin—Oedema—Prednisone—hematologic cancer	5.51e-05	0.000151	CcSEcCtD
Terazosin—Decreased appetite—Betamethasone—hematologic cancer	5.5e-05	0.000151	CcSEcCtD
Terazosin—Decreased appetite—Dexamethasone—hematologic cancer	5.5e-05	0.000151	CcSEcCtD
Terazosin—Nausea—Irinotecan—hematologic cancer	5.49e-05	0.00015	CcSEcCtD
Terazosin—Nausea—Mitoxantrone—hematologic cancer	5.49e-05	0.00015	CcSEcCtD
Terazosin—Back pain—Methotrexate—hematologic cancer	5.46e-05	0.000149	CcSEcCtD
Terazosin—Fatigue—Betamethasone—hematologic cancer	5.46e-05	0.000149	CcSEcCtD
Terazosin—Fatigue—Dexamethasone—hematologic cancer	5.46e-05	0.000149	CcSEcCtD
Terazosin—Pruritus—Etoposide—hematologic cancer	5.44e-05	0.000149	CcSEcCtD
Terazosin—Shock—Prednisone—hematologic cancer	5.42e-05	0.000148	CcSEcCtD
Terazosin—Arrhythmia—Epirubicin—hematologic cancer	5.42e-05	0.000148	CcSEcCtD
Terazosin—Pain—Betamethasone—hematologic cancer	5.41e-05	0.000148	CcSEcCtD
Terazosin—Pain—Dexamethasone—hematologic cancer	5.41e-05	0.000148	CcSEcCtD
Terazosin—Visual impairment—Doxorubicin—hematologic cancer	5.41e-05	0.000148	CcSEcCtD
Terazosin—Tachycardia—Prednisone—hematologic cancer	5.38e-05	0.000147	CcSEcCtD
Terazosin—Nausea—Gemcitabine—hematologic cancer	5.35e-05	0.000146	CcSEcCtD
Terazosin—Vomiting—Cisplatin—hematologic cancer	5.34e-05	0.000146	CcSEcCtD
Terazosin—Hyperhidrosis—Prednisone—hematologic cancer	5.33e-05	0.000146	CcSEcCtD
Terazosin—Vision blurred—Methotrexate—hematologic cancer	5.32e-05	0.000146	CcSEcCtD
Terazosin—Rash—Cisplatin—hematologic cancer	5.29e-05	0.000145	CcSEcCtD
Terazosin—Dermatitis—Cisplatin—hematologic cancer	5.29e-05	0.000145	CcSEcCtD
Terazosin—Malnutrition—Epirubicin—hematologic cancer	5.28e-05	0.000145	CcSEcCtD
Terazosin—Diarrhoea—Etoposide—hematologic cancer	5.26e-05	0.000144	CcSEcCtD
Terazosin—Anorexia—Prednisone—hematologic cancer	5.26e-05	0.000144	CcSEcCtD
Terazosin—Eye disorder—Doxorubicin—hematologic cancer	5.25e-05	0.000144	CcSEcCtD
Terazosin—Ill-defined disorder—Methotrexate—hematologic cancer	5.24e-05	0.000143	CcSEcCtD
Terazosin—Tinnitus—Doxorubicin—hematologic cancer	5.24e-05	0.000143	CcSEcCtD
Terazosin—Feeling abnormal—Betamethasone—hematologic cancer	5.22e-05	0.000143	CcSEcCtD
Terazosin—Feeling abnormal—Dexamethasone—hematologic cancer	5.22e-05	0.000143	CcSEcCtD
Terazosin—Flatulence—Epirubicin—hematologic cancer	5.21e-05	0.000142	CcSEcCtD
Terazosin—Tension—Epirubicin—hematologic cancer	5.18e-05	0.000142	CcSEcCtD
Terazosin—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.18e-05	0.000142	CcSEcCtD
Terazosin—Gastrointestinal pain—Betamethasone—hematologic cancer	5.18e-05	0.000142	CcSEcCtD
Terazosin—Dysgeusia—Epirubicin—hematologic cancer	5.17e-05	0.000142	CcSEcCtD
Terazosin—Hypersensitivity—Triamcinolone—hematologic cancer	5.14e-05	0.000141	CcSEcCtD
Terazosin—Nervousness—Epirubicin—hematologic cancer	5.13e-05	0.00014	CcSEcCtD
Terazosin—Back pain—Epirubicin—hematologic cancer	5.11e-05	0.00014	CcSEcCtD
Terazosin—Malaise—Methotrexate—hematologic cancer	5.09e-05	0.000139	CcSEcCtD
Terazosin—Dizziness—Etoposide—hematologic cancer	5.09e-05	0.000139	CcSEcCtD
Terazosin—Vertigo—Methotrexate—hematologic cancer	5.07e-05	0.000139	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.02e-05	0.000137	CcSEcCtD
Terazosin—Dizziness—Prednisolone—hematologic cancer	5.02e-05	0.000137	CcSEcCtD
Terazosin—Arrhythmia—Doxorubicin—hematologic cancer	5.02e-05	0.000137	CcSEcCtD
Terazosin—Asthenia—Triamcinolone—hematologic cancer	5.01e-05	0.000137	CcSEcCtD
Terazosin—Body temperature increased—Dexamethasone—hematologic cancer	5e-05	0.000137	CcSEcCtD
Terazosin—Abdominal pain—Betamethasone—hematologic cancer	5e-05	0.000137	CcSEcCtD
Terazosin—Abdominal pain—Dexamethasone—hematologic cancer	5e-05	0.000137	CcSEcCtD
Terazosin—Body temperature increased—Betamethasone—hematologic cancer	5e-05	0.000137	CcSEcCtD
Terazosin—Nausea—Cisplatin—hematologic cancer	4.99e-05	0.000136	CcSEcCtD
Terazosin—Insomnia—Prednisone—hematologic cancer	4.99e-05	0.000136	CcSEcCtD
Terazosin—Vision blurred—Epirubicin—hematologic cancer	4.98e-05	0.000136	CcSEcCtD
Terazosin—Paraesthesia—Prednisone—hematologic cancer	4.95e-05	0.000135	CcSEcCtD
Terazosin—Pruritus—Triamcinolone—hematologic cancer	4.94e-05	0.000135	CcSEcCtD
Terazosin—Cough—Methotrexate—hematologic cancer	4.93e-05	0.000135	CcSEcCtD
Terazosin—Ill-defined disorder—Epirubicin—hematologic cancer	4.9e-05	0.000134	CcSEcCtD
Terazosin—Convulsion—Methotrexate—hematologic cancer	4.89e-05	0.000134	CcSEcCtD
Terazosin—Vomiting—Etoposide—hematologic cancer	4.89e-05	0.000134	CcSEcCtD
Terazosin—Malnutrition—Doxorubicin—hematologic cancer	4.89e-05	0.000134	CcSEcCtD
Terazosin—Dyspepsia—Prednisone—hematologic cancer	4.85e-05	0.000133	CcSEcCtD
Terazosin—Rash—Etoposide—hematologic cancer	4.85e-05	0.000133	CcSEcCtD
Terazosin—Dermatitis—Etoposide—hematologic cancer	4.85e-05	0.000133	CcSEcCtD
Terazosin—Headache—Etoposide—hematologic cancer	4.82e-05	0.000132	CcSEcCtD
Terazosin—Flatulence—Doxorubicin—hematologic cancer	4.82e-05	0.000132	CcSEcCtD
Terazosin—Chest pain—Methotrexate—hematologic cancer	4.81e-05	0.000132	CcSEcCtD
Terazosin—Arthralgia—Methotrexate—hematologic cancer	4.81e-05	0.000132	CcSEcCtD
Terazosin—Myalgia—Methotrexate—hematologic cancer	4.81e-05	0.000132	CcSEcCtD
Terazosin—Tension—Doxorubicin—hematologic cancer	4.8e-05	0.000131	CcSEcCtD
Terazosin—Decreased appetite—Prednisone—hematologic cancer	4.79e-05	0.000131	CcSEcCtD
Terazosin—Dysgeusia—Doxorubicin—hematologic cancer	4.79e-05	0.000131	CcSEcCtD
Terazosin—Rash—Prednisolone—hematologic cancer	4.78e-05	0.000131	CcSEcCtD
Terazosin—Dermatitis—Prednisolone—hematologic cancer	4.78e-05	0.000131	CcSEcCtD
Terazosin—Malaise—Epirubicin—hematologic cancer	4.76e-05	0.00013	CcSEcCtD
Terazosin—Fatigue—Prednisone—hematologic cancer	4.75e-05	0.00013	CcSEcCtD
Terazosin—Headache—Prednisolone—hematologic cancer	4.75e-05	0.00013	CcSEcCtD
Terazosin—Discomfort—Methotrexate—hematologic cancer	4.75e-05	0.00013	CcSEcCtD
Terazosin—Nervousness—Doxorubicin—hematologic cancer	4.75e-05	0.00013	CcSEcCtD
Terazosin—Vertigo—Epirubicin—hematologic cancer	4.75e-05	0.00013	CcSEcCtD
Terazosin—Syncope—Epirubicin—hematologic cancer	4.74e-05	0.00013	CcSEcCtD
Terazosin—Back pain—Doxorubicin—hematologic cancer	4.73e-05	0.000129	CcSEcCtD
Terazosin—Constipation—Prednisone—hematologic cancer	4.71e-05	0.000129	CcSEcCtD
Terazosin—Palpitations—Epirubicin—hematologic cancer	4.67e-05	0.000128	CcSEcCtD
Terazosin—Confusional state—Methotrexate—hematologic cancer	4.65e-05	0.000127	CcSEcCtD
Terazosin—Loss of consciousness—Epirubicin—hematologic cancer	4.64e-05	0.000127	CcSEcCtD
Terazosin—Dizziness—Triamcinolone—hematologic cancer	4.61e-05	0.000126	CcSEcCtD
Terazosin—Cough—Epirubicin—hematologic cancer	4.61e-05	0.000126	CcSEcCtD
Terazosin—Anaphylactic shock—Methotrexate—hematologic cancer	4.61e-05	0.000126	CcSEcCtD
Terazosin—Vision blurred—Doxorubicin—hematologic cancer	4.61e-05	0.000126	CcSEcCtD
Terazosin—Convulsion—Epirubicin—hematologic cancer	4.58e-05	0.000125	CcSEcCtD
Terazosin—Nausea—Etoposide—hematologic cancer	4.57e-05	0.000125	CcSEcCtD
Terazosin—Feeling abnormal—Prednisone—hematologic cancer	4.54e-05	0.000124	CcSEcCtD
Terazosin—Asthenia—Betamethasone—hematologic cancer	4.54e-05	0.000124	CcSEcCtD
Terazosin—Asthenia—Dexamethasone—hematologic cancer	4.54e-05	0.000124	CcSEcCtD
Terazosin—Ill-defined disorder—Doxorubicin—hematologic cancer	4.54e-05	0.000124	CcSEcCtD
Terazosin—Thrombocytopenia—Methotrexate—hematologic cancer	4.51e-05	0.000123	CcSEcCtD
Terazosin—Gastrointestinal pain—Prednisone—hematologic cancer	4.51e-05	0.000123	CcSEcCtD
Terazosin—Nausea—Prednisolone—hematologic cancer	4.51e-05	0.000123	CcSEcCtD
Terazosin—Myalgia—Epirubicin—hematologic cancer	4.5e-05	0.000123	CcSEcCtD
Terazosin—Arthralgia—Epirubicin—hematologic cancer	4.5e-05	0.000123	CcSEcCtD
Terazosin—Chest pain—Epirubicin—hematologic cancer	4.5e-05	0.000123	CcSEcCtD
Terazosin—Anxiety—Epirubicin—hematologic cancer	4.48e-05	0.000123	CcSEcCtD
Terazosin—Pruritus—Dexamethasone—hematologic cancer	4.48e-05	0.000123	CcSEcCtD
Terazosin—Pruritus—Betamethasone—hematologic cancer	4.48e-05	0.000123	CcSEcCtD
Terazosin—Hyperhidrosis—Methotrexate—hematologic cancer	4.45e-05	0.000122	CcSEcCtD
Terazosin—Discomfort—Epirubicin—hematologic cancer	4.44e-05	0.000122	CcSEcCtD
Terazosin—Vomiting—Triamcinolone—hematologic cancer	4.44e-05	0.000121	CcSEcCtD
Terazosin—Malaise—Doxorubicin—hematologic cancer	4.41e-05	0.000121	CcSEcCtD
Terazosin—Rash—Triamcinolone—hematologic cancer	4.4e-05	0.00012	CcSEcCtD
Terazosin—Dry mouth—Epirubicin—hematologic cancer	4.4e-05	0.00012	CcSEcCtD
Terazosin—Dermatitis—Triamcinolone—hematologic cancer	4.4e-05	0.00012	CcSEcCtD
Terazosin—Vertigo—Doxorubicin—hematologic cancer	4.39e-05	0.00012	CcSEcCtD
Terazosin—Anorexia—Methotrexate—hematologic cancer	4.39e-05	0.00012	CcSEcCtD
Terazosin—Syncope—Doxorubicin—hematologic cancer	4.38e-05	0.00012	CcSEcCtD
Terazosin—Headache—Triamcinolone—hematologic cancer	4.37e-05	0.00012	CcSEcCtD
Terazosin—Abdominal pain—Prednisone—hematologic cancer	4.36e-05	0.000119	CcSEcCtD
Terazosin—Body temperature increased—Prednisone—hematologic cancer	4.36e-05	0.000119	CcSEcCtD
Terazosin—Confusional state—Epirubicin—hematologic cancer	4.35e-05	0.000119	CcSEcCtD
Terazosin—Diarrhoea—Dexamethasone—hematologic cancer	4.33e-05	0.000119	CcSEcCtD
Terazosin—Diarrhoea—Betamethasone—hematologic cancer	4.33e-05	0.000119	CcSEcCtD
Terazosin—Palpitations—Doxorubicin—hematologic cancer	4.32e-05	0.000118	CcSEcCtD
Terazosin—Anaphylactic shock—Epirubicin—hematologic cancer	4.31e-05	0.000118	CcSEcCtD
Terazosin—Oedema—Epirubicin—hematologic cancer	4.31e-05	0.000118	CcSEcCtD
Terazosin—Hypotension—Methotrexate—hematologic cancer	4.31e-05	0.000118	CcSEcCtD
Terazosin—Loss of consciousness—Doxorubicin—hematologic cancer	4.3e-05	0.000118	CcSEcCtD
Terazosin—Cough—Doxorubicin—hematologic cancer	4.27e-05	0.000117	CcSEcCtD
Terazosin—Shock—Epirubicin—hematologic cancer	4.24e-05	0.000116	CcSEcCtD
Terazosin—Convulsion—Doxorubicin—hematologic cancer	4.24e-05	0.000116	CcSEcCtD
Terazosin—Thrombocytopenia—Epirubicin—hematologic cancer	4.22e-05	0.000116	CcSEcCtD
Terazosin—Tachycardia—Epirubicin—hematologic cancer	4.21e-05	0.000115	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.2e-05	0.000115	CcSEcCtD
Terazosin—Dizziness—Dexamethasone—hematologic cancer	4.19e-05	0.000115	CcSEcCtD
Terazosin—Dizziness—Betamethasone—hematologic cancer	4.19e-05	0.000115	CcSEcCtD
Terazosin—Hyperhidrosis—Epirubicin—hematologic cancer	4.17e-05	0.000114	CcSEcCtD
Terazosin—Insomnia—Methotrexate—hematologic cancer	4.17e-05	0.000114	CcSEcCtD
Terazosin—Myalgia—Doxorubicin—hematologic cancer	4.16e-05	0.000114	CcSEcCtD
Terazosin—Arthralgia—Doxorubicin—hematologic cancer	4.16e-05	0.000114	CcSEcCtD
Terazosin—Chest pain—Doxorubicin—hematologic cancer	4.16e-05	0.000114	CcSEcCtD
Terazosin—Anxiety—Doxorubicin—hematologic cancer	4.15e-05	0.000114	CcSEcCtD
Terazosin—Nausea—Triamcinolone—hematologic cancer	4.14e-05	0.000113	CcSEcCtD
Terazosin—Paraesthesia—Methotrexate—hematologic cancer	4.14e-05	0.000113	CcSEcCtD
Terazosin—Discomfort—Doxorubicin—hematologic cancer	4.11e-05	0.000113	CcSEcCtD
Terazosin—Anorexia—Epirubicin—hematologic cancer	4.11e-05	0.000112	CcSEcCtD
Terazosin—Dyspnoea—Methotrexate—hematologic cancer	4.11e-05	0.000112	CcSEcCtD
Terazosin—Somnolence—Methotrexate—hematologic cancer	4.1e-05	0.000112	CcSEcCtD
Terazosin—Dry mouth—Doxorubicin—hematologic cancer	4.07e-05	0.000111	CcSEcCtD
Terazosin—Hypersensitivity—Prednisone—hematologic cancer	4.06e-05	0.000111	CcSEcCtD
Terazosin—Dyspepsia—Methotrexate—hematologic cancer	4.06e-05	0.000111	CcSEcCtD
Terazosin—Hypotension—Epirubicin—hematologic cancer	4.03e-05	0.00011	CcSEcCtD
Terazosin—Vomiting—Dexamethasone—hematologic cancer	4.03e-05	0.00011	CcSEcCtD
Terazosin—Vomiting—Betamethasone—hematologic cancer	4.03e-05	0.00011	CcSEcCtD
Terazosin—Confusional state—Doxorubicin—hematologic cancer	4.02e-05	0.00011	CcSEcCtD
Terazosin—Decreased appetite—Methotrexate—hematologic cancer	4.01e-05	0.00011	CcSEcCtD
Terazosin—Rash—Dexamethasone—hematologic cancer	3.99e-05	0.000109	CcSEcCtD
Terazosin—Rash—Betamethasone—hematologic cancer	3.99e-05	0.000109	CcSEcCtD
Terazosin—Anaphylactic shock—Doxorubicin—hematologic cancer	3.99e-05	0.000109	CcSEcCtD
Terazosin—Oedema—Doxorubicin—hematologic cancer	3.99e-05	0.000109	CcSEcCtD
Terazosin—Dermatitis—Dexamethasone—hematologic cancer	3.99e-05	0.000109	CcSEcCtD
Terazosin—Dermatitis—Betamethasone—hematologic cancer	3.99e-05	0.000109	CcSEcCtD
Terazosin—Fatigue—Methotrexate—hematologic cancer	3.97e-05	0.000109	CcSEcCtD
Terazosin—Headache—Betamethasone—hematologic cancer	3.97e-05	0.000109	CcSEcCtD
Terazosin—Headache—Dexamethasone—hematologic cancer	3.97e-05	0.000109	CcSEcCtD
Terazosin—Asthenia—Prednisone—hematologic cancer	3.96e-05	0.000108	CcSEcCtD
Terazosin—Pain—Methotrexate—hematologic cancer	3.94e-05	0.000108	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.93e-05	0.000108	CcSEcCtD
Terazosin—Shock—Doxorubicin—hematologic cancer	3.93e-05	0.000107	CcSEcCtD
Terazosin—Thrombocytopenia—Doxorubicin—hematologic cancer	3.91e-05	0.000107	CcSEcCtD
Terazosin—Pruritus—Prednisone—hematologic cancer	3.9e-05	0.000107	CcSEcCtD
Terazosin—Insomnia—Epirubicin—hematologic cancer	3.9e-05	0.000107	CcSEcCtD
Terazosin—Tachycardia—Doxorubicin—hematologic cancer	3.89e-05	0.000107	CcSEcCtD
Terazosin—Paraesthesia—Epirubicin—hematologic cancer	3.87e-05	0.000106	CcSEcCtD
Terazosin—Hyperhidrosis—Doxorubicin—hematologic cancer	3.86e-05	0.000106	CcSEcCtD
Terazosin—Dyspnoea—Epirubicin—hematologic cancer	3.84e-05	0.000105	CcSEcCtD
Terazosin—Somnolence—Epirubicin—hematologic cancer	3.83e-05	0.000105	CcSEcCtD
Terazosin—Anorexia—Doxorubicin—hematologic cancer	3.8e-05	0.000104	CcSEcCtD
Terazosin—Feeling abnormal—Methotrexate—hematologic cancer	3.8e-05	0.000104	CcSEcCtD
Terazosin—Dyspepsia—Epirubicin—hematologic cancer	3.8e-05	0.000104	CcSEcCtD
Terazosin—Diarrhoea—Prednisone—hematologic cancer	3.77e-05	0.000103	CcSEcCtD
Terazosin—Gastrointestinal pain—Methotrexate—hematologic cancer	3.77e-05	0.000103	CcSEcCtD
Terazosin—Nausea—Dexamethasone—hematologic cancer	3.76e-05	0.000103	CcSEcCtD
Terazosin—Nausea—Betamethasone—hematologic cancer	3.76e-05	0.000103	CcSEcCtD
Terazosin—Decreased appetite—Epirubicin—hematologic cancer	3.75e-05	0.000103	CcSEcCtD
Terazosin—Hypotension—Doxorubicin—hematologic cancer	3.73e-05	0.000102	CcSEcCtD
Terazosin—Fatigue—Epirubicin—hematologic cancer	3.72e-05	0.000102	CcSEcCtD
Terazosin—Pain—Epirubicin—hematologic cancer	3.69e-05	0.000101	CcSEcCtD
Terazosin—Constipation—Epirubicin—hematologic cancer	3.69e-05	0.000101	CcSEcCtD
Terazosin—Dizziness—Prednisone—hematologic cancer	3.65e-05	9.98e-05	CcSEcCtD
Terazosin—Body temperature increased—Methotrexate—hematologic cancer	3.64e-05	9.97e-05	CcSEcCtD
Terazosin—Abdominal pain—Methotrexate—hematologic cancer	3.64e-05	9.97e-05	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.63e-05	9.95e-05	CcSEcCtD
Terazosin—Insomnia—Doxorubicin—hematologic cancer	3.61e-05	9.88e-05	CcSEcCtD
Terazosin—Paraesthesia—Doxorubicin—hematologic cancer	3.58e-05	9.8e-05	CcSEcCtD
Terazosin—Dyspnoea—Doxorubicin—hematologic cancer	3.56e-05	9.73e-05	CcSEcCtD
Terazosin—Feeling abnormal—Epirubicin—hematologic cancer	3.55e-05	9.72e-05	CcSEcCtD
Terazosin—Somnolence—Doxorubicin—hematologic cancer	3.55e-05	9.71e-05	CcSEcCtD
Terazosin—Gastrointestinal pain—Epirubicin—hematologic cancer	3.53e-05	9.65e-05	CcSEcCtD
Terazosin—Dyspepsia—Doxorubicin—hematologic cancer	3.51e-05	9.61e-05	CcSEcCtD
Terazosin—Vomiting—Prednisone—hematologic cancer	3.51e-05	9.59e-05	CcSEcCtD
Terazosin—Rash—Prednisone—hematologic cancer	3.48e-05	9.51e-05	CcSEcCtD
Terazosin—Dermatitis—Prednisone—hematologic cancer	3.47e-05	9.5e-05	CcSEcCtD
Terazosin—Decreased appetite—Doxorubicin—hematologic cancer	3.47e-05	9.49e-05	CcSEcCtD
Terazosin—Headache—Prednisone—hematologic cancer	3.45e-05	9.45e-05	CcSEcCtD
Terazosin—Fatigue—Doxorubicin—hematologic cancer	3.44e-05	9.41e-05	CcSEcCtD
Terazosin—Pain—Doxorubicin—hematologic cancer	3.41e-05	9.34e-05	CcSEcCtD
Terazosin—Constipation—Doxorubicin—hematologic cancer	3.41e-05	9.34e-05	CcSEcCtD
Terazosin—Abdominal pain—Epirubicin—hematologic cancer	3.41e-05	9.33e-05	CcSEcCtD
Terazosin—Body temperature increased—Epirubicin—hematologic cancer	3.41e-05	9.33e-05	CcSEcCtD
Terazosin—Hypersensitivity—Methotrexate—hematologic cancer	3.39e-05	9.29e-05	CcSEcCtD
Terazosin—Asthenia—Methotrexate—hematologic cancer	3.31e-05	9.05e-05	CcSEcCtD
Terazosin—Feeling abnormal—Doxorubicin—hematologic cancer	3.29e-05	9e-05	CcSEcCtD
Terazosin—Nausea—Prednisone—hematologic cancer	3.27e-05	8.96e-05	CcSEcCtD
Terazosin—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.26e-05	8.93e-05	CcSEcCtD
Terazosin—Pruritus—Methotrexate—hematologic cancer	3.26e-05	8.92e-05	CcSEcCtD
Terazosin—Hypersensitivity—Epirubicin—hematologic cancer	3.18e-05	8.69e-05	CcSEcCtD
Terazosin—Body temperature increased—Doxorubicin—hematologic cancer	3.15e-05	8.63e-05	CcSEcCtD
Terazosin—Abdominal pain—Doxorubicin—hematologic cancer	3.15e-05	8.63e-05	CcSEcCtD
Terazosin—Diarrhoea—Methotrexate—hematologic cancer	3.15e-05	8.63e-05	CcSEcCtD
Terazosin—Asthenia—Epirubicin—hematologic cancer	3.09e-05	8.47e-05	CcSEcCtD
Terazosin—Pruritus—Epirubicin—hematologic cancer	3.05e-05	8.35e-05	CcSEcCtD
Terazosin—Dizziness—Methotrexate—hematologic cancer	3.05e-05	8.34e-05	CcSEcCtD
Terazosin—Diarrhoea—Epirubicin—hematologic cancer	2.95e-05	8.07e-05	CcSEcCtD
Terazosin—Hypersensitivity—Doxorubicin—hematologic cancer	2.94e-05	8.04e-05	CcSEcCtD
Terazosin—Vomiting—Methotrexate—hematologic cancer	2.93e-05	8.02e-05	CcSEcCtD
Terazosin—Rash—Methotrexate—hematologic cancer	2.91e-05	7.95e-05	CcSEcCtD
Terazosin—Dermatitis—Methotrexate—hematologic cancer	2.9e-05	7.94e-05	CcSEcCtD
Terazosin—Headache—Methotrexate—hematologic cancer	2.89e-05	7.9e-05	CcSEcCtD
Terazosin—Asthenia—Doxorubicin—hematologic cancer	2.86e-05	7.83e-05	CcSEcCtD
Terazosin—Dizziness—Epirubicin—hematologic cancer	2.85e-05	7.8e-05	CcSEcCtD
Terazosin—Pruritus—Doxorubicin—hematologic cancer	2.82e-05	7.72e-05	CcSEcCtD
Terazosin—Vomiting—Epirubicin—hematologic cancer	2.74e-05	7.5e-05	CcSEcCtD
Terazosin—Nausea—Methotrexate—hematologic cancer	2.74e-05	7.49e-05	CcSEcCtD
Terazosin—Diarrhoea—Doxorubicin—hematologic cancer	2.73e-05	7.47e-05	CcSEcCtD
Terazosin—Rash—Epirubicin—hematologic cancer	2.72e-05	7.44e-05	CcSEcCtD
Terazosin—Dermatitis—Epirubicin—hematologic cancer	2.72e-05	7.43e-05	CcSEcCtD
Terazosin—Headache—Epirubicin—hematologic cancer	2.7e-05	7.39e-05	CcSEcCtD
Terazosin—Dizziness—Doxorubicin—hematologic cancer	2.64e-05	7.22e-05	CcSEcCtD
Terazosin—Nausea—Epirubicin—hematologic cancer	2.56e-05	7.01e-05	CcSEcCtD
Terazosin—Vomiting—Doxorubicin—hematologic cancer	2.54e-05	6.94e-05	CcSEcCtD
Terazosin—Rash—Doxorubicin—hematologic cancer	2.52e-05	6.88e-05	CcSEcCtD
Terazosin—Dermatitis—Doxorubicin—hematologic cancer	2.51e-05	6.88e-05	CcSEcCtD
Terazosin—Headache—Doxorubicin—hematologic cancer	2.5e-05	6.84e-05	CcSEcCtD
Terazosin—Nausea—Doxorubicin—hematologic cancer	2.37e-05	6.49e-05	CcSEcCtD
Terazosin—ADRA1B—Signaling Pathways—KITLG—hematologic cancer	1.06e-05	0.000102	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CD—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL2RA—hematologic cancer	1.04e-05	0.000101	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTT1—hematologic cancer	1.04e-05	0.000101	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—IL2—hematologic cancer	1.04e-05	0.0001	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—STAT5A—hematologic cancer	1.03e-05	0.0001	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CREB1—hematologic cancer	1.03e-05	0.0001	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TERT—hematologic cancer	1.03e-05	9.99e-05	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CB—hematologic cancer	1.03e-05	9.98e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN2B—hematologic cancer	1.02e-05	9.92e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—STAT1—hematologic cancer	1.02e-05	9.89e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—SDC1—hematologic cancer	1.02e-05	9.86e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3R1—hematologic cancer	1.01e-05	9.82e-05	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	1.01e-05	9.79e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CCL2—hematologic cancer	1.01e-05	9.79e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL6R—hematologic cancer	1.01e-05	9.76e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PDGFB—hematologic cancer	1.01e-05	9.75e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3R1—hematologic cancer	9.91e-06	9.6e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CD86—hematologic cancer	9.91e-06	9.6e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—JAK2—hematologic cancer	9.85e-06	9.54e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TSC2—hematologic cancer	9.84e-06	9.53e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HES1—hematologic cancer	9.77e-06	9.46e-05	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	9.75e-06	9.44e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NCOR1—hematologic cancer	9.71e-06	9.41e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—JAK2—hematologic cancer	9.64e-06	9.33e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CSF2—hematologic cancer	9.61e-06	9.3e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FGF1—hematologic cancer	9.61e-06	9.3e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—MAP2K1—hematologic cancer	9.6e-06	9.3e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—GRB2—hematologic cancer	9.55e-06	9.25e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CD—hematologic cancer	9.53e-06	9.24e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PDGFA—hematologic cancer	9.53e-06	9.23e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FOXO1—hematologic cancer	9.47e-06	9.17e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FGFR3—hematologic cancer	9.47e-06	9.17e-05	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—IL2—hematologic cancer	9.46e-06	9.17e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PDGFRB—hematologic cancer	9.45e-06	9.15e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KITLG—hematologic cancer	9.39e-06	9.1e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAPK14—hematologic cancer	9.37e-06	9.08e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CB—hematologic cancer	9.36e-06	9.06e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PDGFRA—hematologic cancer	9.3e-06	9.01e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—JAK1—hematologic cancer	9.27e-06	8.98e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PRKCG—hematologic cancer	9.27e-06	8.98e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ESR1—hematologic cancer	9.19e-06	8.91e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—STAT5A—hematologic cancer	9.18e-06	8.89e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CB—hematologic cancer	9.15e-06	8.87e-05	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	9.12e-06	8.84e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN2B—hematologic cancer	9.1e-06	8.81e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FN1—hematologic cancer	9.08e-06	8.8e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3R1—hematologic cancer	9e-06	8.72e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NFKBIA—hematologic cancer	8.97e-06	8.69e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—BAD—hematologic cancer	8.97e-06	8.69e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NOTCH1—hematologic cancer	8.89e-06	8.61e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CD86—hematologic cancer	8.8e-06	8.52e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—JAK2—hematologic cancer	8.75e-06	8.48e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CD80—hematologic cancer	8.71e-06	8.43e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CG—hematologic cancer	8.69e-06	8.42e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KIT—hematologic cancer	8.69e-06	8.42e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—NRAS—hematologic cancer	8.69e-06	8.42e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HES1—hematologic cancer	8.68e-06	8.41e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL2RA—hematologic cancer	8.66e-06	8.39e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CD44—hematologic cancer	8.65e-06	8.38e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NQO1—hematologic cancer	8.65e-06	8.38e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NCOR1—hematologic cancer	8.63e-06	8.36e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL2—hematologic cancer	8.59e-06	8.32e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TERT—hematologic cancer	8.56e-06	8.29e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PTPN11—hematologic cancer	8.54e-06	8.27e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGF1—hematologic cancer	8.53e-06	8.26e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CSF2—hematologic cancer	8.53e-06	8.26e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FOXO1—hematologic cancer	8.41e-06	8.15e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—IL2—hematologic cancer	8.4e-06	8.14e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PDGFRB—hematologic cancer	8.39e-06	8.13e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PDGFB—hematologic cancer	8.36e-06	8.09e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—MAPK3—hematologic cancer	8.32e-06	8.06e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CB—hematologic cancer	8.31e-06	8.05e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CREB1—hematologic cancer	8.27e-06	8.01e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PDGFRA—hematologic cancer	8.26e-06	8e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—JAK1—hematologic cancer	8.24e-06	7.98e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PRKCG—hematologic cancer	8.24e-06	7.98e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYCS—hematologic cancer	8.19e-06	7.93e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—BRAF—hematologic cancer	8.17e-06	7.91e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TSC2—hematologic cancer	8.17e-06	7.91e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—HSP90AA1—hematologic cancer	8.13e-06	7.88e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CCL2—hematologic cancer	8.09e-06	7.84e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL6R—hematologic cancer	8.07e-06	7.82e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CREBBP—hematologic cancer	8.06e-06	7.81e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FGFR3—hematologic cancer	7.86e-06	7.61e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAPK14—hematologic cancer	7.78e-06	7.54e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL2RA—hematologic cancer	7.69e-06	7.45e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAP2K1—hematologic cancer	7.69e-06	7.45e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CD—hematologic cancer	7.64e-06	7.4e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL2—hematologic cancer	7.63e-06	7.39e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ESR1—hematologic cancer	7.63e-06	7.39e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TERT—hematologic cancer	7.6e-06	7.37e-05	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PIK3CA—hematologic cancer	7.57e-06	7.33e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FN1—hematologic cancer	7.54e-06	7.3e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—KRAS—hematologic cancer	7.48e-06	7.25e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—BAD—hematologic cancer	7.45e-06	7.21e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NFKBIA—hematologic cancer	7.45e-06	7.21e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PDGFB—hematologic cancer	7.42e-06	7.19e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NOTCH1—hematologic cancer	7.38e-06	7.15e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FGF2—hematologic cancer	7.32e-06	7.09e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TSC2—hematologic cancer	7.25e-06	7.03e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CD80—hematologic cancer	7.23e-06	7e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTP1—hematologic cancer	7.21e-06	6.99e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3R1—hematologic cancer	7.21e-06	6.99e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CG—hematologic cancer	7.21e-06	6.99e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KIT—hematologic cancer	7.21e-06	6.99e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—NRAS—hematologic cancer	7.21e-06	6.99e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PTPN11—hematologic cancer	7.09e-06	6.86e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—JAK2—hematologic cancer	7.01e-06	6.79e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGFR3—hematologic cancer	6.98e-06	6.76e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	6.91e-06	6.69e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—MAPK3—hematologic cancer	6.91e-06	6.69e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PIK3CA—hematologic cancer	6.87e-06	6.66e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CREB1—hematologic cancer	6.87e-06	6.65e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MDM2—hematologic cancer	6.84e-06	6.63e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—BRAF—hematologic cancer	6.78e-06	6.57e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	6.78e-06	6.57e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CCL2—hematologic cancer	6.72e-06	6.51e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL6R—hematologic cancer	6.7e-06	6.49e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FN1—hematologic cancer	6.7e-06	6.49e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CREBBP—hematologic cancer	6.69e-06	6.48e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MTOR—hematologic cancer	6.66e-06	6.45e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CB—hematologic cancer	6.66e-06	6.45e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NCOR1—hematologic cancer	6.63e-06	6.42e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTM1—hematologic cancer	6.63e-06	6.42e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	6.62e-06	6.41e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—BAD—hematologic cancer	6.62e-06	6.41e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	6.55e-06	6.35e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CD80—hematologic cancer	6.42e-06	6.22e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	6.41e-06	6.21e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KIT—hematologic cancer	6.41e-06	6.21e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	6.41e-06	6.21e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAP2K1—hematologic cancer	6.38e-06	6.18e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—HRAS—hematologic cancer	6.36e-06	6.16e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CD—hematologic cancer	6.34e-06	6.14e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	6.29e-06	6.1e-05	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CA—hematologic cancer	6.28e-06	6.08e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1B—hematologic cancer	6.25e-06	6.05e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—KRAS—hematologic cancer	6.21e-06	6.01e-05	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—AKT1—hematologic cancer	6.18e-06	5.99e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	6.14e-06	5.94e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CASP3—hematologic cancer	6.13e-06	5.93e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL2—hematologic cancer	6.12e-06	5.92e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	6.1e-06	5.91e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—IL6—hematologic cancer	6.09e-06	5.89e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FGF2—hematologic cancer	6.07e-06	5.88e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	6.02e-06	5.83e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3R1—hematologic cancer	5.99e-06	5.8e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	5.97e-06	5.78e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CCND1—hematologic cancer	5.96e-06	5.78e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	5.95e-06	5.76e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—JUN—hematologic cancer	5.95e-06	5.76e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	5.94e-06	5.75e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—MTHFR—hematologic cancer	5.86e-06	5.68e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—JAK2—hematologic cancer	5.82e-06	5.64e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1A—hematologic cancer	5.77e-06	5.59e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PTEN—hematologic cancer	5.75e-06	5.57e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CA—hematologic cancer	5.7e-06	5.53e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MDM2—hematologic cancer	5.68e-06	5.5e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	5.67e-06	5.49e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	5.63e-06	5.46e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAPK8—hematologic cancer	5.63e-06	5.45e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—AKT1—hematologic cancer	5.61e-06	5.44e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	5.58e-06	5.4e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MTOR—hematologic cancer	5.53e-06	5.35e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CB—hematologic cancer	5.53e-06	5.35e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	5.51e-06	5.34e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EP300—hematologic cancer	5.49e-06	5.32e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	5.39e-06	5.22e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—SRC—hematologic cancer	5.34e-06	5.17e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	5.32e-06	5.15e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	5.28e-06	5.11e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—VEGFA—hematologic cancer	5.2e-06	5.03e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	5.19e-06	5.02e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	5.17e-06	5.01e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—STAT3—hematologic cancer	5.15e-06	4.99e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NRAS—hematologic cancer	5.13e-06	4.97e-05	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	5.13e-06	4.97e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	5.08e-06	4.92e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL2—hematologic cancer	5.08e-06	4.92e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	5.07e-06	4.91e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	5.05e-06	4.89e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	5.05e-06	4.89e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	4.95e-06	4.79e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—JUN—hematologic cancer	4.94e-06	4.78e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CG—hematologic cancer	4.92e-06	4.77e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAPK3—hematologic cancer	4.92e-06	4.76e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	4.91e-06	4.76e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	4.91e-06	4.76e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	4.79e-06	4.64e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MYC—hematologic cancer	4.78e-06	4.63e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	4.78e-06	4.63e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	4.77e-06	4.62e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	4.69e-06	4.54e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	4.67e-06	4.53e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	4.66e-06	4.51e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	4.61e-06	4.46e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CREBBP—hematologic cancer	4.56e-06	4.42e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	4.56e-06	4.41e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EP300—hematologic cancer	4.55e-06	4.41e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	4.52e-06	4.37e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL2—hematologic cancer	4.51e-06	4.37e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	4.49e-06	4.35e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SRC—hematologic cancer	4.43e-06	4.29e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	4.42e-06	4.28e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	4.4e-06	4.26e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—JUN—hematologic cancer	4.39e-06	4.25e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CD—hematologic cancer	4.33e-06	4.19e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	4.31e-06	4.18e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ALB—hematologic cancer	4.27e-06	4.14e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	4.27e-06	4.14e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	4.26e-06	4.13e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	4.25e-06	4.12e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	4.24e-06	4.11e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	4.15e-06	4.02e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	4.14e-06	4.01e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3R1—hematologic cancer	4.09e-06	3.96e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	4.08e-06	3.95e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	4.06e-06	3.93e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EP300—hematologic cancer	4.05e-06	3.92e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MYC—hematologic cancer	3.97e-06	3.84e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	3.96e-06	3.84e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SRC—hematologic cancer	3.93e-06	3.81e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TP53—hematologic cancer	3.93e-06	3.8e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	3.83e-06	3.71e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	3.79e-06	3.68e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	3.78e-06	3.67e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CB—hematologic cancer	3.77e-06	3.65e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	3.76e-06	3.64e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	3.67e-06	3.55e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	3.62e-06	3.51e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL6—hematologic cancer	3.59e-06	3.48e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MYC—hematologic cancer	3.53e-06	3.42e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	3.52e-06	3.41e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	3.37e-06	3.26e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	3.32e-06	3.21e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PTEN—hematologic cancer	3.26e-06	3.16e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TP53—hematologic cancer	3.26e-06	3.16e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	3.26e-06	3.16e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	3.12e-06	3.02e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—EP300—hematologic cancer	3.11e-06	3.01e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	2.99e-06	2.9e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL6—hematologic cancer	2.98e-06	2.89e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TP53—hematologic cancer	2.9e-06	2.8e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	2.77e-06	2.68e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	2.75e-06	2.67e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL6—hematologic cancer	2.65e-06	2.57e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	2.44e-06	2.37e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CA—hematologic cancer	2.3e-06	2.23e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—AKT1—hematologic cancer	1.88e-06	1.82e-05	CbGpPWpGaD
